home / stock / wpdpf / wpdpf news
WPD Pharmaceuticals (WPDPF) announces that it plans to commence a phase Ib/II study of berubicin for the treatment of glioblastoma ((GBM)) in the second half of this year.CNS Pharmaceuticals (CNSP), the company that sublicenses the compound to WPD for 30 countries mainly in Europe...
WPD Pharmaceuticals (WPDPF) announces that it has been conditionally awarded a grant of $6.7M from the Polish National Center for Research and Development (“NCRD”), for the development of annamycin, the company’s drug candidate used in the treatment of Acute Myeloid ...
WPD Pharmaceuticals (WPDPF) has signed an agreement with CNS Pharmaceuticals (CNSP) to obtain Investigational Medicinal Product ((IMP)) for use in the planned clinical trials of Berubicin.Berubicin is a novel anthracycline candidate for the treatment of a number of serious oncology ...